Current understanding and management of CAR T cell-associated toxicities

JN Brudno, JN Kochenderfer - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …

Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado… - Frontiers in …, 2023 - frontiersin.org
Lymphodepletion (LD) or conditioning is an essential step in the application of currently
used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it …

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

K Rejeski, DK Hansen, R Bansal, P Sesques… - Journal of Hematology & …, 2023 - Springer
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …

[PDF][PDF] Cooperative CAR targeting to selectively eliminate AML and minimize escape

S Haubner, J Mansilla-Soto, S Nataraj, F Kogel… - Cancer Cell, 2023 - cell.com
Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

K Rejeski, Y Wang, DK Hansen, G Iacoboni… - Blood …, 2024 - ashpublications.org
Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can
predispose for severe infectious complications. Current grading systems, such as the …

The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following …

K Rejeski, Y Wang, O Albanyan… - American journal of …, 2023 - Wiley Online Library
Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel)
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …

Antitumor efficacy and safety of unedited autologous CD5. CAR T cells in relapsed/refractory mature T-cell lymphomas

LQC Hill, RH Rouce, MJ Wu, T Wang, R Ma, H Zhang… - Blood, 2024 - ashpublications.org
Despite newer targeted therapies, patients with primary refractory or relapsed (r/r) T-cell
lymphoma have a poor prognosis. The development of chimeric antigen receptor (CAR) T …

Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and …

E Galli, A Fresa, S Bellesi, E Metafuni… - European Journal of …, 2024 - Wiley Online Library
Impaired function of hematopoiesis after treatment with chimeric antigen T‐cells (CAR‐T) is
a frequent finding and can interest a wide range of patients, regardless of age and …

Human herpes virus-6 (HHV-6) reactivation after hematopoietic cell transplant and chimeric antigen receptor (CAR)-T cell therapy: a shifting landscape

E Kampouri, G Handley, JA Hill - Viruses, 2024 - mdpi.com
HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant
(HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following …

Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity

EC Liang, K Rejeski, T Fei, A Albittar… - Bone Marrow …, 2024 - nature.com
Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy,
resulting in significant morbidity and mortality. In an effort to standardize reporting, the …